HARNESSING THE POWER OF IMMUNOTHERAPY

Immunotherapy could revolutionize cancer care by developing nontoxic, highly efficient and decisive cures that do not rely on chemotherapeutic agents. These treatments could be used in 60% of advanced cancer patients by 2025. Canada needs greater capacity to translate these therapies into patient care, and to help Canadian companies compete in a potential $40 billion market.

A “ONE-STOP-SHOP” SOLUTION

A Canadian “one-stop-shop” solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine.
C3i Combines five interacting units:

• GMP Manufacturing
• Biomarker-Diagnostic
• Clinical Research
• CRO
• Innovation and Commercialization

C3i

C3i (Centre for Commercialisation of Cancer Immunotherapy) , a CECR (Centre of Excellence for Commercialisation and Research) from the NCE (Networks of Centres of Excellence) will accelerate access to innovative cancer immunotherapies for patients. 

Operating out of the Hôpital Maisonneuve- Rosemont in Montreal, Canada, C3i offers an integrated structure for the development, translation and commercialization of these ground breaking therapies